Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities, J. Rheumatol. Suppl, vol.85, pp.2-10, 2010. ,
Optimizing use of tumor necrosis factor inhibitors in the management of immunemediated inflammatory diseases, J. Rheumatol. Suppl, vol.85, pp.40-52, 2010. ,
IL-1 pathways in inflammation and human diseases, Nat. Rev. Rheumatol, vol.6, pp.232-241, 2010. ,
The value of blocking IL-6 outside of rheumatoid arthritis: current perspective, Curr. Opin. Rheumatol, vol.23, pp.273-277, 2011. ,
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring, Lancet Neurol, vol.10, pp.745-758, 2011. ,
Interferon therapy in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of the comparative trials, J. Neurol. Sci, vol.302, pp.96-105, 2011. ,
Rheumatoid arthritis: when should we use rituximab to treat RA?, Nat. Rev. Rheumatol, vol.7, pp.379-380, 2011. ,
Adverse effects of biologics: a network meta-analysis and Cochrane overview, Cochrane Database Syst. Rev, p.8794, 2011. ,
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases, Lancet Neurol, vol.9, pp.438-446, 2010. ,
Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies, Annu. Rev. Med, vol.61, pp.35-47, 2010. ,
CD28 superagonists: what makes the difference in humans?, Immunity, vol.28, pp.591-595, 2008. ,
, A model for harmonizing flow cytometry in clinical trials, vol.11, pp.975-978, 2010.
Standardizing immunophenotyping for the Human Immunology Project, Nat. Rev. Immunol, vol.12, pp.191-200, 2012. ,